Terms: = Colorectal cancer AND FES, FPS, 2242, ENSG00000182511, P07332 AND Prognosis
4 results:
1. Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD.
Chen M; Zhang X; Ming Z; Lingyu ; Feng X; Han Z; An HX
J Transl Med; 2024 Mar; 22(1):315. PubMed ID: 38539235
[TBL] [Abstract] [Full Text] [Related]
2. How I treat stage II colon cancer patients.
Taieb J; Karoui M; Basile D
ESMO Open; 2021 Aug; 6(4):100184. PubMed ID: 34237612
[TBL] [Abstract] [Full Text] [Related]
3. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
[TBL] [Abstract] [Full Text] [Related]
4. Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials.
Sakamoto J; Hamada C; Kodaira S; Nakazato H; Ohashi Y
Jpn J Clin Oncol; 1999 Feb; 29(2):78-86. PubMed ID: 10089948
[TBL] [Abstract] [Full Text] [Related]
